Can trametinib be reimbursed by medical insurance?

Trametinib, an oral agent developed by GlaxoSmithKline (GSK), was approved by the US FDA on May 29, 2013. It has become an important drug for the treatment of unresectable or metastatic melanoma associated with BRAF (Murine Sarcoma Oncogenic Homolog B1 gene) V600E or V600K mutations. Its trade name is Mekinist, which mainly works by inhibiting MEK 1/2 (mitogen-activated extracellular signal-regulated kinase 1/2), thereby blocking the proliferation of cancer cells.

Although trametinib is effective in treating specific melanomas, its use may also be accompanied by some side effects, such as allergic reactions, blood clots, bleeding, etc. Therefore, patients need to pay close attention to body reactions when using it and communicate with their doctor in a timely manner.

The good news is that trametinib has been included in my country's medical insurance directory, which means that patients can enjoy medical insurance reimbursement when purchasing this drug. The original trametinib on the domestic market has a specification of 30 tablets of 2 mg per box, and the price after reimbursement by medical insurance is less than 12,000 yuan per box, which undoubtedly reduces the financial burden on patients.

In addition, generic versions of trametinib have been launched in overseas markets, many of which are produced and sold by pharmaceutical factories in Laos. The specifications of these generic drugs are the same as the original ones, but the price is more affordable, about 1,900 yuan per box. According to patient feedback, these generic drugs work well and provide patients with more choices. Of course, when choosing drugs, patients are advised to consult professional overseas medical consultants based on their actual conditions.